HORMONES 2003, 2(3):183-185
DOI: 
Case report
Macroprolactinemia. Is treatment necessary?
Irene V. Lambrinoudaki1, Olga D. Daskalaki2, Stathis A. Thomopoulos2, Panayiotis Schinochoritis3, Argyris B. Argyropoulos2

12nd Department of Obstetrics and Gynecology, University of Athens, School of Medicine, "Aretaieion" Hospital, 2Department of Endocrinology, Diabetes and Metabolism "Agios Panteleimon" District General Hospital of Nikea, Piraeus, Greece, 3Biomedicine International Diagnostic Services

Abstract

A 26-year old symptom-free woman was admitted to our Clinic for evaluation of hyperprolactinemia. The patient, who had normal menstrual cycles, was found accidentally to have a cystic adnexal mass and was placed on oral contraceptives (OC) for 3 months. During the first OC-cycle a bilateral breast nipple discharge was noticed and an elevated serum prolactin (PRL) was detected (2.7 nmol/l). The OC was discontinued and bromocriptine therapy was started. Serum PRL levels were restored and spontaneous menses resumed. The Pituitary magnetic resonance imaging (MRI), the anterior pituitary function, assessed by dynamic tests, and the thyroid hormone levels were normal. Upon bromocriptine discontinuation, PRL levels increased to 13.8 nmol/l. Poly-ethylene-glycol precipitation of the patient's serum, in two consecutive measurements, demonstrated the presence of macroprolactinemia. Since the patient was asymptomatic, a dopamine agonist was not resumed. Macroprolactinemia is characterized by most authors, as a benign condition with no clinical implications. However, a number of investigators challenge this view, suggesting that in some cases mild symptomatology is present possibly requiring therapeutic intervention.

Keywords

Hyperprolactinemia, macroprolactinemia


Read PDF

INTRODUCTION

In the majority of patients with hyperprolactinemia monomeric prolactin (PRL) namely PRL with a molecular weight of 23K DA predominates. Nevertheless, in some patients with hyperprolactinemia high molecular weight forms of PRL are primarily detected. These forms of PRL are the big PRL (molecular weight 50-60 K DA) and the big-big PRL (macroprolactin) with a molecular weight greater than 100 K DA.

Macroprolactinemia is a term applied to cases with high prolactin concentrations in which big-big prolactin predominates. In such cases the recognition of high molecular weight PRL can be achieved by gel filtration chromatography or by a simplified method using polyethylene glycol precipitation (PEG). If macroprolactin is present in serum it is precipitated by glycol while the monomeric remains in the supernatant. The introduction of the latter method has greatly facilitated the diagnosis of macroprolactinemia which is suspected when high prolactin values are detected in asymptomatic patients.

In the present report we describe a woman with hyperprolactinema, accidentally detected and in whom macroprolactinemia was finally diagnosed.

CASE REPORT

A 26-year old white woman was admitted to our Clinic for evaluation of hyperprolactinemia detected 6 months previously. The patient had spontaneous menarche at age 11 and normal menstrual periods since then. Her cycles were of 28 days duration and menstrual bleeding lasted 4-5 days. The patient had undergone total thyroidectomy for multinodular goiter and had been on L-thyroxine substitution therapy (150mg per day). During a period of psychological distress she noticed midcycle bleeding, lasting 2-5 days, for two consecutive months. Because of this she was subjected to pelvic ultrasonography which revealed a 5.5 x 4cm cystic right adnexal mass. The patient was subsequently placed on therapy with oral contraceptives (OC) for three months. During that period the patient noticed bilateral breast nipple discharge. Serum prolactin (PRL) measured for the first time was found 2.7nmol/l. Oral contraceptives were discontinued and bromocriptine therapy (5mg/day) was advised by her private gynecologist without further work-up. Under this treatment, serum PRL levels returned to normal (0.29nmol/l) and the menstrual cycles were regular following oral contraceptive withdrawal. After 4 months of bromocriptine therapy, an attempt was made to discontinue bromocriptine treatment. Two weeks after stopping bromocriptine, serum PRL levels increased to 13.8nmol/l.

The patient was admitted to our endocrine ward for complete work-up of her hyperprolactinemia. During her hospitalization the serum PRL levels ranged from 4.5-8.4nmol/l. Pituitary gland MRI was normal. The thyroid hormone levels were within normal limits: (TSH 0.1mIU/l, FT3 0.43pmol/l, FT4 19.3pmol/l. Anterior pituitary function, assessed by IV insulin tolerance test, was normal. Pregnancy was excluded by a low β-HCG level (1mIU/l).

The serum PRL levels were subsequently measured after precipitation of the patient's serum with poly-ethylene-glycol. With this method, serum PRL levels were normal on two consecutive measurements (0.61 and 0.65nmol/l). The patient was discharged from our hospital with the diagnosis of macroprolactinemia and without any medication. Following her discharge she has been symptom-free and reports regular menstrual cycles lasting 28 days.

DISCUSSION

Macroprolactinemia has been repeatedly documented as a cause of elevated PRL levels over the past two decades1. Prolactin circulates in human serum in three forms: 1) monomeric PRL (molecular weight 23 Kdalton), which is the usual form and has the highest biologic activity, 2) big PRL (molecular weight 50-60 Kdalton) and 3) big _ big PRL or macroprolactin (molecular weight 150-170 Kdalton). The last two forms seem to result from complexes of monomeric PRL with PRL-binding antibodies and have reduced biologic activity due to their difficulty in crossing the capillary wall2-5. The PRL-binding antibodies act as a buffer system for the monomeric PRL molecules and are responsible for pseudo-hyperprolactinemia.

The prevalence of macroprolactinemia ranges from 10-30% of hyperprolactinemic patients, depending on the method employed and the definition used6-8. The most validated method for the detection of macroprolactinemia is gel filtration chromatography which, however, is expensive and difficult to perform7. Recently, a simpler screening method using polyethylene glycol (PEG) has been employed for the detection of macroprolactinemia. Macroprolactin, if present in the serum, is precipitated by prior incubation with PEG. In general, recovery rates less than 40% are attributed to macroprolactinemia6,8-10.

The clinical relevance of macroprolactinemia is a matter of debate. The majority of patients with macroprolactinemia lack the classical symptoms of PRL excess, such as menstrual irregularities, galactorrhea or subfertility, and have normal pituitary gland on MRI. Dopamine agonists, therefore, are not necessary and many clinicians feel that no pharmacological intervention and only careful follow-up is warranted11-15. This view, however, has recently been questioned. Vallette-Kasic6 reported a series of 106 patients with macroprolactinemia followed up over a 10-year period. Although the majority of these patients were asymptomatic and had uneventful pregnancies, a number of patients reported symptoms associated with hyperprolactinemia such as menstrual irregularities or subfertility. The dilemma of therapeutic intervention is exaggerated by MRI findings suggestive of a pituitary adenoma. In such cases the question as to whether or not this is a coincidental, non-functioning adenoma or is related to the hyperprolactinemia is difficult to answer. Our patient was completely asympto-matic and ovulation was confirmed in two consecutive cycles by measuring serum progesterone levels on day 21 of the menstrual cycle. Therefore, we could not ascribe a clinical relevance to macroprolactinemia except for the occasional nipple discharge. The normalization of prolactin level in our patient by the initial administration of biomocryptine is not easily explained. It is possible that the hyperprolactinemia previously detected was a response to her reported stress which led to the antibody formation and subsequent macroprolactinemia detected during hospitalization in our clinic. As regards the therapeutic intervention, the final choice of treatment in cases of macroprolactinemia should be individualized. In the majority of cases the condition is benign and no treatment is required. In certain cases, however, especially when symptoms are present, a trial of dopamine agonist treatment may be warranted.

REFERENCES
1. Leslie H, Courtney CH, Bell PM, et al, 2001 Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 86: 2743-2746.
2. Sapin R, Gasser F, Grucker D, 2002 Free prolactin determinations in hyperprolactinemic men with suspicion of macroprolactinemia. Clin Chim Acta 316: 33-41.
3. Cavaco B, Leite V, Santos MA, Arranhado E, Sobrinho LG, 1995 Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J Clin Endocrinol Metab 80: 2342-2346.
4. Leite V, Cosby H, Sobrinho LG, Fresnoza MA, Santos MA, Friesen HG, 1992 Characterization of big, big prolactin in patients with hyperprolactinaemia. Clin Endocrinol 37: 365-372.
5. Jackson RD, Wortsman J, Malarkey WB, 1985 Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol Metab 61: 258-264.
6. Vallette-Kasic S, Morange-Ramos I, Selim A, et al, 2002 Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 87: 581-588.
7. Fahie-Wilson MN, Soule SG, 1997 Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem 34: 252-258.
8. Olukoga AO, Kane JW, 1999 Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol 51: 119-126.
9. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H, 1994 Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. Eur J Endocrinol 130: 438-445.
10. Fideleff HL, Ruibal G, Boquete H, Pujol A, Sequera A, Sobrado P, 2000 Macroprolactinemia in childhood and adolescence: a cause of asymptomatic hyperprolactinemia. Horm Res 53: 16-19.
11. Whittaker PG, Wilcox T, Lind T, 1981 Maintained fertility in a patient with hyperprolactinemia due to big, big prolactin. J Clin Endocrinol Metab 53: 863-866.
12. Fraser IS, Lun ZG, Zhou JP, et al, 1989 Detailed assessment of big big prolactin in women with hyperprolactinemia and normal ovarian function. J Clin Endocrinol Metab 69: 585-592.
13. Corenblum B, 1990 Asymptomatic hyperprolactinemia resulting from macroprolactinemia. Fertil Steril 53: 165-167.
14. Vassilatou E, Schinochoritis P, Marioli S, Tzavara I, 2003 Macroprolactinemia in a young man and review of the literature. Hormones 2: 130-134.
15. Olukoga AO, 2002 Macroprolactinemia is clinically important. J Clin Endocrinol Metab 87: 4833-4834.

 

Address correspondence and requests for reprints to:
Irene Lambrinoudaki, MD, Lecturer, University of Athens,
School of Medicine, 27, Themistokleous Street, Dionysos,
GR-14578, Athens, Greece, Tel. & Fax: +30 210 8137716,
e-mail:ilambrinoudaki@hotmail.com

Received 06-06-03, Revised 23-06-03, Accepted 30-06-03


FEATURED ARTICLES

NEWSLETTER